Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Sanofi to Take Over Japan MA for Beyfortus from AstraZeneca
Sanofi will assume the Japanese marketing authorization for the anti-respiratory syncytial virus (RSV) antibody Beyfortus (nirsevimab) from AstraZeneca starting in August, the two companies said on July 18. The partners will continue to co-promote the product. According to Sanofi, the…
To read the full story
Related Article
- Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
- Sanofi Launches Epidemiological Study for Beyfortus in Japan
April 7, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- Single-Injection Beyfortus Will Reduce Burdens on Parents and Children: Experts
June 10, 2024
- AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
BUSINESS
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…